论文部分内容阅读
美国西南肿瘤组织(ＳＷＯＧ)进行了用大剂量阿糖胞苷(Ａｒａ－Ｃ)和大剂量米托蒽醌作为诱导方案治疗复发性或难治性成人急性淋巴细胞白血病(ＡＬＬ)的Ⅱ期临床试验,以探讨该方案的疗效。方法 经形态学诊断的成人ＡＬＬ３１例。
Southwestern Cancer Organisation (SWOG) performed phase II clinical trials of high-dose cytarabine (Ara-C) and high-dose mitoxantrone as an induction regimen for the treatment of relapsed or refractory adult acute lymphoblastic leukemia (ALL) Test to explore the efficacy of the program. Methods Morphologically diagnosed 31 cases of adult ALL.